US44486Q1031 - Common Stock
HUMACYTE INC
NASDAQ:HUMA (12/23/2024, 8:11:05 PM)
After market: 4.6 -0.05 (-1.08%)4.65
+0.01 (+0.22%)
Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company is headquartered in Durham, North Carolina and currently employs 183 full-time employees. The company went IPO on 2020-09-22. The firm is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The firm has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. The company is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. The Company’s scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved.
HUMACYTE INC
2525 East North Carolina Highway 54
Durham NORTH CAROLINA
P: 19193139633
CEO: Rajiv Shukla
Employees: 184
Website: https://humacyte.com/
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA...
Here you can normally see the latest stock twits on HUMA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: